Asensus Surgical (ASXC) Q2 Earnings call transcript Aug 13, 2024
AInvestWednesday, Aug 14, 2024 3:27 pm ET
1min read
ASXC --

In the latest earnings call for Asensus Surgical, the company provided updates on its financial performance and the status of its proposed merger with Karl Storz. The call, led by President and CEO Anthony Fernando and CFO Shameze Rampertab, highlighted the company's financial results and the potential implications of the merger on its future.

Financial Overview

The second quarter of 2024 saw a significant increase in revenue for Asensus Surgical, with a reported $2.2 million in revenue compared to $1.1 million in the same period last year. The company's revenue breakdown included system revenue of $0.8 million, lease revenue of $0.6 million, instruments and accessories at $0.6 million, and services at $0.2 million. Despite the revenue growth, the company reported a net loss attributable to common stockholders of $25.7 million or $0.09 per share, compared to $20.7 million or $0.09 per share in the same quarter last year. The adjusted net loss attributable to common stockholders was $18.1 million, a decrease from the previous year's adjusted net loss of $23 million.

Merger Proposal with Karl Storz

The most notable topic of discussion during the call was the proposed merger with Karl Storz. The merger, which would see Asensus Surgical acquired by Karl Storz Endoscopy America, is not yet approved by stockholders, with only 55% of outstanding shares having been voted on. The company is currently seeking stockholder approval for the merger, which requires a majority of all outstanding shares to pass. If approved, the merger would provide a significant return to stockholders, despite the disappointment of a lower price than some initial investments.

Financial Implications

The potential rejection of the merger proposal could have severe financial consequences for Asensus Surgical. The company would face significant near-term financial obligations, including a repayment to Karl Storz of their $20 million securitized note plus interest and payment premiums, as well as transaction expenses. These obligations, which exceed the available capital on the company's balance sheet, could potentially lead to bankruptcy protection if the merger is not approved. In such a scenario, common stockholders may receive less than the merger consideration or no distributions at all.

Conclusion

Asensus Surgical's second quarter financial update and the proposed merger with Karl Storz highlight the company's current financial situation and the potential impact of the merger on its future. Despite the challenges, the company remains optimistic about the potential benefits of the merger and the return it could offer to stockholders. As the merger proposal awaits stockholder approval, it is crucial for investors to closely monitor the situation and consider the potential outcomes. The company's financial health and future prospects hinge on the success of this merger, making every stockholder's participation in the vote essential.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.